JAK1 and B-cell non-Hodgkin lymphoma: A phase 1 dose-escalation/expansion study evaluated the safety and efficacy of dezapelisib, a new selective PI3Kδ inhibitor, as monotherapy or in combination with itacitinib, a selective JAK1 inhibitor, in adult patients with relapsed B-cell lymphomas.